{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening; requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG000","title":"Part 2 (Open-Label Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"From Day 1 of Part 2 up to Week 24 of Part 2 + 1 day","title":"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}